Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
FinCEN and DOJ Appeal Corporate Transparency Act Nationwide Injunction Two Days After Texas Ruling on BOIR
-
Vision Marine and Armada Partner to Produce an Innovative Electric Pontoon for North America’s Regulated Lakes
-
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
-
RBB Law Group Partners with Amazon to Transform Car Buying and Ensure Fair Rebates Nationwide
-
EliteSignals Unveils Revolutionary Forex Trading Bot: EliteX
-
DKbitex to Launch DKBC: A Revolutionary New Cryptocurrency
-
Hosted.com Launches AI-Powered Domain Name Generator, Simplifying The Domain Registration Process
-
Staking AI Redefines Crypto Investments: Discover the Highest APY Platform of 2024
-
ZeusX Celebrates Milestones in Connecting Gamers Through a Secure Marketplace
-
PRIME MINISTER OF MONGOLIA MAKES HISTORIC VISIT TO MIDDLE EAST
-
Icona Capital Acquires Island In Maldives for an Ultra-Luxury Project
-
Global Times: Clay Figure Zhang's works naturally reflect spiritual state of the times
-
DKbitex to Launch DKDC: A Revolutionary New Cryptocurrency
-
University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
-
Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Orca Bio Presents Clinical Results on Use of Orca-Q® without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
-
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
-
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
-
Twenty-three Years Running for the Kids of St. Jude: St. Jude Memphis Marathon Weekend Reaches Fundraising Record
-
Caribbean Airlines Brings the Region Closer with New Service to Guadeloupe
-
New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients
-
MosquitoMate receives first Vector Expedited Review Voucher (VERV) from the US Environmental Protection Agency
-
Pennsylvania Skill, powered by Pace-O-Matic, Responds to Commonwealth Court Ruling in Favor of Skill Games
-
Building Homes for Heroes Gifts 400th Home, Marking Historic Achievement in Veteran and First Responder Support
-
HII Christens Virginia-Class Attack Submarine Arkansas (SSN 800)
-
United Flow Technologies Acquires The TDH Company to Enhance Water and Wastewater Treatment Solutions
-
Admirals Group AS Announces a Sale of its Australian Subsidiary
-
OpsHub Amplifies its Presence on the Visual Studio (VSTS) Marketplace
-
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relaps
-
Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic Leukemia
-
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
-
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
-
Guan Hu's BLACK DOG Nominated for Best International Film For Film Independent Spirit Award
-
Edwards Lifesciences Corporation Investors: December 13, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
-
Fred Says Foundation Announces Its 2024 Gifts for World AIDS Day
-
Frank Biden: the Importance of COVID-19 Class Action Lawsuits in Pursuit of Justice and Accountability
-
Privee AI Announces New Magic AI Studio
-
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
-
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeti
-
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Ind
-
MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting
-
Ethara: THE ART OF CURATING THE ABU DHABI GRAND PRIX HOSPITALITY EXPERIENCE
-
ACHC Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Acadia Healthcare Company, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit
-
Researchers Report New Opportunities to Improve Quality of Life for People with Non-Malignant Blood Disorders
-
Phase 2 data from the ongoing HIBISCUS study shows promise that investigational etavopivat could reduce the incidence of vaso-occlusive crises in people with sickle cell disease
-
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
